Ferring Pharmaceuticals

Ferring Pharmaceuticals, Royalty Pharma, nadofaragene firadenovec, Bladder cancer, non-muscle invasive bladder cancer, Adstiladrin

Ferring Strikes $500M Agreement with Royalty Pharma for Innovative Bladder Cancer Gene Therapy

Anika Sharma

Royalty Pharma has carved a distinctive niche in the pharmaceutical landscape, specializing in identifying innovative products both pre- and post-approval, ...